Jefferies Raises Price Target on EZCORP (EZPW) to $6 Following 2Q
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq hits intraday record high on tech boost, Mideast negotiation hopes
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil prices rise on Trump timeline for Iran peace deal: after US elections
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Unusual 11 Mid-Day Movers 5/10: (CCXI) (CROX) (SODA) Higher; (EPRS) (NLNK) (JGW) Lower
May 10, 2016 12:50 PM EDTEPIRUS Biopharmaceuticals, Inc. (Nasdaq: EPRS) 55.1% LOWER; announced reprioritization of the companys pipeline to focus exclusively on developing biosimilars for the treatment of rare diseases. This includes reallocating the Companys resources to focus on the development of BOW080 (eculizumab; reference biologic Soliris®) for the potential treatment of ultra-rare blood disorders and BOW070 (tocilizumab; reference biologic Actemra) for the potential treatment of an uncommon lymphoproliferative disorder known as Castlemans disease.
ChemoCentryx, Inc. (Nasdaq: CCXI) 41.0% HIGHER; Vifor Pharmaand and... More
